Role of TRPV4 mechanotransduction in foreign body response
Role of TRPV4 mechanotransduction in foreign body response
批准号:
9365090
负责人:
Shaik O Rahaman
金额:
$43.56万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-10 至 2021-06-30
关键词:
AblationAdhesionsAffectAtomic Force MicroscopyAttenuatedBiocompatible MaterialsBiological ModelsBone MarrowBone Marrow TransplantationCell membraneCessation of lifeChronicCollagenCoupledDataDevelopmentDevicesDiseaseEncapsulatedFailureFamilyFibrosisForeign BodiesForeign-Body Giant CellsGene ExpressionGenerationsGeneticGoalsHumanImplantInflammationInflammation MediatorsInflammatoryInterleukin-4International AspectsIon ChannelLeadLinkMacrophage ActivationMechanicsMechanoreceptorsMediatingMediator of activation proteinMedicalMedical DeviceModelingMolecularMorbidity - disease rateMusMyofibroblastOrganPathogenesisPathway interactionsPatientsPharmacologyPhosphatidylinositolsPhosphotransferasesProceduresProtein IsoformsRegulationResearchRoleSeveritiesSignal TransductionTestingTissuesTractionVanilloidbasecell motilityfibrogenesishigh throughput screeningimplantationin vitro Modelin vivoinhibitor/antagonistinnovative technologiesinsightintraperitonealloss of functionmacrophagemechanotransductionmortalitymouse modelnovelnovel therapeuticspreventreceptorresponsesmall moleculesubcutaneous
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Implantable biomaterials and medical devices are used in millions of procedures each year worldwide.
However, in large number of patients, the implantation of these devices often leads to the development of a
foreign body response (FBR), a chronic inflammatory condition that can ultimately lead to implant failure, which
may cause harm to or death of the patient. The FBR consists of persistent inflammation coupled with fibrous
encapsulation around the implant. There are no effective medical treatments. Hallmarks of the FBR include
activation of macrophages at the tissue-implant interface, formation of destructive foreign body giant cells
(FBGCs), and development of fibrous tissue that encapsulates the implant. The overall goal of our research is
to understand the molecular mechanisms of the fibrotic response. Activated macrophages are thought to
orchestrate the FBR by secreting inflammatory mediators. Emerging data support a critical role for a
mechanical signal, e.g., substrate stiffness, in macrophage activation. However, a critical gap in this field is that
the identity of the plasma membrane mechanosensor by which the mechanical signal is transduced/maintained
is not known, nor are the downstream consequences of mechano-receptor signaling on the FBR. These gaps
pose a significant barrier to progress in the field. In recent, exciting preliminary data, we obtained evidence that
TRPV4, an ion channel in the transient receptor potential vanilloid family, and which is a known
mechanosensor, may be the mediator of FBR. Specifically, we found that: 1) Trpv4 deletion in mice prevented
macrophage accumulation, FBGC formation, and collagen accumulation in a subcutaneous implantation
model; 2) the severity of the in vivo macrophage accumulation at the tissue-implant interface was dependent
on the stiffness of the implant, and 3) genetic ablation or pharmacologic antagonism of TRPV4 blocked
macrophage adhesion and spreading on stiff matrix, interleukin-4-induced FBGC formation, and inflammatory
gene expression in both human and mouse bone marrow derived macrophages. Our preliminary data indicated
that TRPV4 activity (Ca2+ influx) was augmented in response to increased matrix stiffness, and suggested that
the molecular pathway linking TRPV4 activity to the FBR involved a specific phosphoinositide 3-kinase (PI3K)
isoform, PI3K-alpha. The objective of this proposal is to determine the role of TRPV4 in the FBR. Based on our
preliminary data, our central hypothesis is that TRPV4 mediates the FBR to biomaterials by increasing
macrophage activation and fibrogenesis in a manner dependent on substrate stiffness and PI3K-alpha. We will
utilize innovative technologies, in vivo and in vitro model systems, and a recently identified small molecule
TRPV4 inhibitor to test the hypothesis with two Specific Aims. In Specific Aim 1 we will test the hypothesis that
TRPV4 is a necessary component of the FBR in vivo; and in Specific Aim 2 we will test the hypothesis that
mechanosensing by TRPV4 is a key component of the molecular mechanism of regulation of biomaterial-
induced macrophage activation and fibrogenesis. When completed, we expect that the results of this study will
generate novel information and insight regarding the mechanisms mediating the FBR to biomaterials, and will
potentially identify a targetable receptor/pathway for the amelioration of FBR.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金